skip to Main Content
[font_awesome icon="phone"] 1-800-987-654[font_awesome icon="envelope"] [email protected][font_awesome icon="user"][wp_login_url text="User Login" logout_text="Logout"]

Motor skills of people with Parkinson’s improve by 50% after medical research study


News and research before you hear about it on CNBC and others. Claim your one week free trial for StreetInsider Premium here.


LAS VEGAS, June 21, 2022 (GLOBE NEWSWIRE) — Zhittya Genesis Medicine, Inc. (a private company) (“Zhittya”), announced that they will host a webinar on June 23, 2022 at 3:00 p.m. PT, presenting evidence and analysis of improvements in people with Parkinson’s disease in the Zhittya Medical Research Study. To register for this webinar and see the visual and analytical improvements in motor function for people with Parkinson’s, visit zgm.care.

Analysis of motor scores indicates that the human subjects had a 50% improvement in their motor skills. Zhittya’s study used its biologic drug candidate human FGF-1 in conjunction with a proprietary intranasal delivery device to deliver its drug into the brain. Patients received two increasing doses of FGF-1 intranasally and were monitored for adverse events. So far, no adverse events have been observed in the subjects during the medical research study nor after the conclusion of the dosage regimen. Video analysis, patient surveys, and principal investigator observations show promising signs of motor and cognitive improvement.

Again, Zhittya will host a free Zoom webinar titled: Medical research study in Parkinson’s disease: first look at data from intranasal administration of FGF-1. This webinar will air at 3:00 p.m. PT on Thursday, June 23, 2022. Viewers will learn about the results of this completed research study and will be able to see the first-hand data on the safety and efficacy tests collected . so far. To register for the webinar, please visit the company’s website: zgm.care.

Over the past five years, a new medical hypothesis has been proposed that Parkinson’s disease may be triggered by vascular disruption in areas of the brain that house dopamine-producing neurons. The theory holds that over time, the micro-vasculature in the brain becomes blocked, shrinks, or leaks, causing blood flow to be restricted, which prevents affected neurons from receiving adequate nourishment. This disruption of a natural biological process can lead to the classic symptoms of Parkinson’s disease, including tremors and difficulty walking. Very promising improvements in motor tests have been observed with FGF-1 in models of Parkinson’s disease in rodents and primates. In these models, FGF-1 has been shown to act as a “disease modifying agent” by regenerating new dopamine-secreting neurons. These neurons become dysfunctional in Parkinson’s disease and are widely recognized as the root cause of the disease. Zhittya’s administration believes that this medical research study not only brings Zhittya’s FGF-1 closer to market, but could also be considered a disease-modifying agent in the treatment of Parkinson’s disease.

Again, Zhittya’s free Zoom webinar on early human results from our study of intranasal administration of FGF-1 in subjects with Parkinson’s disease will air on June 23, 2022 at 3:00 p.m. PT ( 6 p.m. EST). , go to: zgm.care

About Zhittya Genesis MedicineZhittya Genesis Medicine, Inc. advances a group of drugs that trigger the human body’s natural regeneration process. Our medicine initiates a biological response in the human body called “therapeutic angiogenesis”, which only occurs in diseased tissues that become ischemic due to a lack of blood flow. In areas with poor blood flow, the drug stimulates the growth of new blood vessels, providing nourishment and removing metabolic wastes, thus restoring normal cell functions. In addition to the brain disorders described above, the company also has promising evidence that FGF-1 is a potential new treatment for coronary heart disease, peripheral arterial disease (PAD) and diabetic foot ulcers. Currently, more than 75 human diseases are known to be caused by a lack of blood flow to a tissue or organ. The company’s management has been dedicated to advancing its proprietary medicines for more than 23 years and has spent more than US$150 million to date to support these efforts. To learn more, please visit: zgm.care

Zhitya contact:

Daniel Montano, CEOZhittya Genesis Medicine, Inc.702-802-8373 [email protected]

main logo

Source: Zhittya Genesis Medicine Inc.

Back To Top